!
About
Tallac Therapeutics™ is a privately held clinical stage biopharmaceutical company based in the San Francisco Bay Area. Our multi-disciplinary team is rapidly advancing company’s lead oncology programs in multiple indications. Tallac’s pipeline of oligonucleotide-based ADC candidates includes novel Toll-like Receptor Agonist Antibody Conjugates (TRAAC) to systemically deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) and trigger immune activation within the tumor microenvironment. Several TRAAC molecules are in various stages of discovery and development, including two programs in the clinic.
#### Tallac team
!!
### Hong I. Wan
President, CEO and
Co-founder
### Curtis Hecht
Chief Business Officer
### Laura Chou
Interim Chief
Medical Officer
### Pavel Strop
Vice President,
Research
### Bora Han
Preclinical Development
### Mark Karbarz
Executive Director,
 Biologics Development
### Emma Abellana
Senior Director,
Finance
### Maria Costa
 Head of Biology and Translational Research
### Sangeetha Bollini
Director,
Preclinical Operations
### Ryan Quick
Director, CMC
### Stacy Fide
Associate Director,
Study Management
### Ons Harrabi
Clinical Biomarkers
### Maja Bonacorsi
Principal Scientist
### Amy Chen
### Emma Sangalang
### Danielle Fontaine
Scientific Associate II
### Verwina Roble
Sr. Accountant / Office Manager
#### board of directors
### Mike Carusi
### Isaac Cheng
### Peter Dudek
### Corey Goodman
Chairman and Co-founder
### Jaume Pons
President, CEO and Co-founder
#### Investors
!!!!!
* (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Envelope
Copyright © 2020-2025 Tallac Therapeutics, Inc. All Rights Reserved.
Our Science
Tallac’s novel technology allows precise conjugation of therapeutic oligo payloads, expanding beyond the conventional toxin payloads and enabling the precise and systemic delivery of next gen therapies such as CpG oligonucleotides (TLR9 Agonist), antisense oligonucleotides, and siRNA. Tallac’s most advanced programs leverage the power of clinically validated CpG oligonucleotides to activate immune cells to fight cancer.  We developed a novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent TLR9 agonist (T-CpG) for targeted immune activation via systemic administration.
#### Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
Tallac’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform enables systemic delivery of a differentiated, targeted TLR9 agonist (T-CpG) for immune activation.
#### TRAAC
* T-CpG is comprised of monomeric CpG-containing oligonucleotides optimized for potency and stability as an antibody conjugate.
* TRAAC utilizes site-specific conjugation, allowing precise control of the positioning and number of T-CpG molecules conjugated. This in turn enables fine tuning of the conjugate activity.
* The activation of specific immune cell populations systemically or in the local tumor microenvironment is achieved by selecting the appropriate cellular targets and antibodies for T-CpG conjugation.
News
 News
Select year
 2024
 2023
 2022
 2021
 2020
[* **9 Jul, 2024**
### Biospace features Tallac Therapeutics as an antibody-drug conjugate (ADC) drug developer
[* **24 Jun, 2024**
### Clarivate for Life Sciences & Healthcare highlights Tallac Therapeutics as one of the seven Companies to Watch that are revolutionizing antibody drug conjugates (ADCs).
[* **10 Apr, 2024**
### Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
[* **3 Nov, 2023**
### Tallac Presents First Clinical Data for TAC-001 at SITC 2023
[* **27 Sep, 2023**
### Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
[* **11 Nov, 2022**
### Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
[* **28 Jul, 2022**
### Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
[* **19 May, 2022**
### Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
[* **21 Oct, 2021**
### Tallac SITC 2021 Presentation
[* **15 Apr, 2021**
### Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
[* **12 Apr, 2021**
### Tallac AACR 2021 Presentation
[* **12 Mar, 2021**
### AACR 2021 presentation on preclinical data for TAC-001
[* **4 Mar, 2021**
### ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
[* **1 Dec, 2020**
### Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
[* **5 Nov, 2020**
### SITC 2020 Presentation
 Biospace features Tallac Therapeutics as an antibody-drug conjugate (ADC) drug developer
Posted 9 Jul, 2024
## Biospace features Tallac Therapeutics as an antibody-drug conjugate (ADC) drug developer
We’ve been featured in an article titled “Drug Developers Tap the Immune System to Supercharge ADCs” which was published in **Biospace** this week. This article discusses the growth of the antibody drug conjugate market and explores the potential of immunostimulatory antibody drug conjugates (iADCs).
In this piece, Hong I. Wan, CEO of Tallac Therapeutics, discusses the features of Tallac’s TAC-001, a TLR9 agonist ADC, and how it could potentially benefit a broader patient population with increased safety and tolerability.
Read the full article here: 
 July
 9
 June
 24
 April
 10
 Clarivate for Life Sciences & Healthcare highlights Tallac Therapeutics as one of the seven Companies to Watch that are revolutionizing antibody drug conjugates (ADCs).
Posted 24 Jun, 2024
## Clarivate for Life Sciences & Healthcare highlights Tallac Therapeutics as one of the seven Companies to Watch that are revolutionizing antibody drug conjugates (ADCs).
Clarivate released the 2024 Companies to Watch report, highlighting seven innovative companies advancing antibody drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects.
#### DOWNLOAD
 Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Posted 10 Apr, 2024
## Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
*~ TAC-001, Tallac’s lead immunostimulatory ADC program, potentiates cancer vaccine efficacy and rejuvenates immune responses in preclinical studies ~*
---
**BURLINGAME, California, April 10, 2024 (BUSINESS WIRE) —** Tallac Therapeutics, Inc., a privately held clinical stage biopharmaceutical company pioneering the discovery and development of novel antibody-oligonucleotide conjugates, today announced the presentation of preclinical data demonstrating TAC-001 potentiates cancer vaccine efficacy and rejuvenates vaccine responses. TAC-001 is an investigational, systemically delivered, Toll-like Receptor Agonist Antibody Conjugate (TRAAC) molecule, designed to selectively activate B cells to drive an anti-tumor immune response. The data will be presented today as part of the Vaccines, Antigens, and Antigen Presentation 2 session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taking place in San Diego, April 5-10, 2024.
The findings presented in the poster “**A B cell targeted TLR9 Agonist Antibody Conjugate Potentiates Cancer Vaccine Efficacy and Rejuvenates** **Vaccine Responses in the Elderly**” demonstrate that in combination with cancer vaccines, TAC-001 promotes robust and durable vaccine specific IgG titers, skews humoral response to Th1 phenotype, and rejuvenates vaccine responses. Moreover, TAC-001 enhances vaccine specific T cell activation and cytotoxic activity. As a result, anti-tumor vaccine efficacy is greatly improved by the combination with TAC-001. “The emerging data on TAC-001 in combination with cancer vaccines enhances our understanding of TAC-001 mechanisms in eliciting humoral and cellular anti-tumor immunity and provide a compelling rationale for combining TAC-001 with cancer vaccines in the clinic. This preclinical proof of concept expands the prospective therapeutic application of TAC-001 in oncology and other disease indications” said Dr. Hong I. Wan, president, CEO, and co-founder of Tallac Therapeutics.
**AACR Poster Presentation Details:**
* **Title:** “A B cell targeted TLR9 Agonist Antibody Conjugate Potentiates Cancer Vaccine Efficacy and Rejuvenates Vaccine Responses in the Elderly.”
* **Session Type:** Poster Session
* **Session Category:** Immunology
* **Session Title:** Vaccines, Antigens, and Antigen Presentation 2
* **Abstract Number:** 6746
* **Section 4,** April 10, 9:00AM-12:30PM
**About TAC-001 (CD22 TRAAC)**
TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC) comprised of a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22, a receptor restricted to B cells, including tumor-infiltrating B cells. TAC-001 is designed to systemically deliver T-CpG to B cells by binding to CD22, leading to internalization of TAC-001, TLR9 signaling, B cell activation and a cascade of immune reactions.  demonstrate that the innate and adaptive immune responses triggered by TAC-001 lead to potent anti-tumor activity. TAC-001 is being developed for the treatment of solid tumors and is currently in a Phase 1/2 Study in cancer patients (). Emerging clinical data demonstrating tolerability, pharmacodynamic activity and preliminary clinical activity of single agent TAC-001 were observed ().
**About Tallac Therapeutics, Inc.**
Tallac Therapeutics is a privately held clinical stage biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer using next generation ADCs. Tallac’s pipeline of immunostimulatory ADC candidates is derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and development. TAC-001, the company’s lead clinical candidate, is currently in an ongoing Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. For more information, please visit .
**Tallac Contact:**
Curtis Hecht, CBO
650.651.3559
checht@tallactx.com